West Pharmaceutical Services Quarterly Income Statement
NYSE: WSTHealthcareMedical Instruments & SuppliesUSD
At close: Oct 9, 4:02 PM ET · Delayed 15 min
West Pharmaceutical Services revenue and earnings
In the quarter ended Jun 30, 2026, West Pharmaceutical Services generated $872.3 million in revenue, up 13.8% from the same quarter a year earlier. Net income was $154.0 million (+16.8% year over year), for a net margin of 17.7% versus a median of 16.4% in the prior 5 quarters. Gross margin was 37.7% (up from 35.7%) and operating margin 20.5%.
Diluted earnings per share came in at $2.15, up from $1.82.
Summary generated from market data by MetaCap's automated system. Methodology
West Pharmaceutical Services income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 872.30M | 844.90M | 805.00M | 804.60M | 766.50M | 698.00M | 748.80M | 746.90M | 702.10M | 695.40M | 732.00M | 747.40M |
| Revenue growth (YoY) | +13.80% | +21.05% | +7.51% | +7.73% | +9.17% | +0.37% | +2.30% | -0.07% | -6.86% | -2.96% | +3.29% | +8.81% |
| Cost of Revenue | 543.10M | 548.50M | 501.10M | 510.30M | 492.60M | 466.10M | 475.20M | 482.20M | 472.10M | 465.20M | 453.80M | 459.10M |
| Gross Profit | 329.20M | 296.40M | 303.90M | 294.30M | 273.90M | 231.90M | 273.60M | 264.70M | 230.00M | 230.20M | 278.20M | 288.30M |
| Operating Expenses | 150.10M | 119.30M | 147.30M | 126.70M | 120.20M | 124.90M | 114.00M | 103.40M | 103.80M | 107.40M | 117.30M | 111.00M |
| Research & Development | 19.70M | 15.80M | 21.80M | 17.10M | 19.10M | 16.30M | 18.50M | 15.50M | 17.50M | 17.60M | 18.40M | 16.40M |
| Selling, General & Admin | 117.60M | 99.50M | 107.00M | 102.70M | 95.90M | 88.00M | 85.30M | 83.50M | 83.00M | 86.70M | 90.00M | 89.00M |
| Operating Income | 179.10M | 177.10M | 156.60M | 167.60M | 153.70M | 107.00M | 159.60M | 161.30M | 126.20M | 122.80M | 160.90M | 177.30M |
| Interest Expense | 2.60M | 1.90M | -200.00K | 200.00K | 100.00K | 400.00K | -800.00K | 700.00K | 1.50M | 1.60M | 1.20M | 2.90M |
| Other Income (Expense) | -200.00K | -200.00K | -400.00K | -200.00K | -200.00K | -200.00K | -300.00K | 3.20M | 2.50M | 4.60M | 7.30M | 9.70M |
| Pretax Income | 180.10M | 180.10M | 161.50M | 171.90M | 157.00M | 110.50M | 164.90M | 164.50M | 128.70M | 127.40M | 168.20M | 187.00M |
| Income Tax | 32.20M | 44.70M | 33.30M | 34.00M | 30.20M | 24.10M | 36.80M | 32.40M | 21.90M | 16.40M | 34.50M | 29.40M |
| Net Income | 154.00M | 138.80M | 132.10M | 140.00M | 131.80M | 89.80M | 130.10M | 136.00M | 111.30M | 115.30M | 137.00M | 161.30M |
| Net Income growth (YoY) | +16.84% | +54.57% | +1.54% | +2.94% | +18.42% | -22.12% | -5.04% | -15.69% | -28.24% | -17.64% | +33.01% | +33.75% |
| EPS (Basic) | 2.17 | 1.93 | 1.83 | 1.94 | 1.82 | 1.24 | 1.79 | 1.87 | 1.52 | 1.57 | 1.85 | 2.17 |
| EPS (Diluted) | 2.15 | 1.92 | 1.82 | 1.92 | 1.82 | 1.23 | 1.78 | 1.85 | 1.51 | 1.55 | 1.83 | 2.14 |
| Shares Outstanding (Basic) | 70.80M | 72.00M | — | 72.20M | 72.20M | 72.50M | — | 72.80M | 73.00M | 73.50M | — | 74.30M |
| Shares Outstanding (Diluted) | 71.30M | 72.40M | — | 72.60M | 72.50M | 73.00M | — | 73.40M | 73.70M | 74.30M | — | 75.30M |
| EBITDA | 225.30M | 222.30M | 203.60M | 210.60M | 195.10M | 147.00M | 200.30M | 201.50M | 165.10M | 158.40M | 195.50M | 212.10M |
| Gross Margin | 37.74% | 35.08% | 37.75% | 36.58% | 35.73% | 33.22% | 36.54% | 35.44% | 32.76% | 33.10% | 38.01% | 38.57% |
| Operating Margin | 20.53% | 20.96% | 19.45% | 20.83% | 20.05% | 15.33% | 21.31% | 21.60% | 17.97% | 17.66% | 21.98% | 23.72% |
| Net Margin | 17.65% | 16.43% | 16.41% | 17.40% | 17.20% | 12.87% | 17.37% | 18.21% | 15.85% | 16.58% | 18.72% | 21.58% |
This table shows 12 quarterly periods of West Pharmaceutical Services's income statement, from Q2 2026 back to Q3 2023, across 20 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow WST's reporting calendar. What is a income statement?